Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Foghorn Therapeutics Inc. | fhtx-20210331xex312.htm |
| EX-32.1 - EX-32.1 - Foghorn Therapeutics Inc. | fhtx-20210331xex321.htm |
| EX-31.1 - EX-31.1 - Foghorn Therapeutics Inc. | fhtx-20210331xex311.htm |
| 10-Q - 10-Q - Foghorn Therapeutics Inc. | fhtx-20210331.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Foghorn Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| Date: May 11, 2021 | |||||
| /s/ Allan Reine | |||||
| Allan Reine, M.D. Chief Financial Officer (Principal Accounting and Financial Officer) | |||||